Bailard Inc. lifted its holdings in Global Blood Therapeutics Inc (NASDAQ:GBT) by 59.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 72,700 shares of the company’s stock after purchasing an additional 27,000 shares during the period. Bailard Inc.’s holdings in Global Blood Therapeutics were worth $2,861,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors have also made changes to their positions in the company. Goldman Sachs Group Inc. increased its stake in shares of Global Blood Therapeutics by 211.7% in the 2nd quarter. Goldman Sachs Group Inc. now owns 317,571 shares of the company’s stock valued at $8,686,000 after purchasing an additional 215,690 shares in the last quarter. Family Management Corp acquired a new stake in Global Blood Therapeutics in the 3rd quarter worth about $351,000. Perceptive Advisors LLC boosted its holdings in Global Blood Therapeutics by 8.4% in the 3rd quarter. Perceptive Advisors LLC now owns 4,264,066 shares of the company’s stock worth $132,399,000 after buying an additional 330,139 shares during the last quarter. State Board of Administration of Florida Retirement System boosted its holdings in Global Blood Therapeutics by 38.6% in the 3rd quarter. State Board of Administration of Florida Retirement System now owns 17,759 shares of the company’s stock worth $551,000 after buying an additional 4,950 shares during the last quarter. Finally, Janus Henderson Group PLC acquired a new stake in Global Blood Therapeutics in the 2nd quarter worth about $26,919,000. Hedge funds and other institutional investors own 85.95% of the company’s stock.
Several research firms recently issued reports on GBT. Janney Montgomery Scott began coverage on Global Blood Therapeutics in a report on Tuesday. They issued a “buy” rating and a $75.00 price objective on the stock. ValuEngine upgraded Global Blood Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. William Blair began coverage on Global Blood Therapeutics in a report on Tuesday, January 23rd. They issued an “outperform” rating and a $80.00 price objective on the stock. HC Wainwright set a $73.00 price objective on Global Blood Therapeutics and gave the stock a “buy” rating in a report on Thursday, January 11th. Finally, Cantor Fitzgerald set a $61.00 price objective on Global Blood Therapeutics and gave the stock a “buy” rating in a report on Monday, December 11th. Two research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $65.80.
Global Blood Therapeutics Inc (NASDAQ:GBT) opened at $62.30 on Thursday. Global Blood Therapeutics Inc has a twelve month low of $21.85 and a twelve month high of $65.40.
TRADEMARK VIOLATION WARNING: “Global Blood Therapeutics Inc (GBT) Position Boosted by Bailard Inc.” was originally published by Markets Daily and is owned by of Markets Daily. If you are accessing this article on another domain, it was stolen and republished in violation of US & international copyright law. The correct version of this article can be viewed at https://www.themarketsdaily.com/2018/02/15/global-blood-therapeutics-inc-gbt-position-boosted-by-bailard-inc.html.
About Global Blood Therapeutics
Global Blood Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD).
Want to see what other hedge funds are holding GBT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Global Blood Therapeutics Inc (NASDAQ:GBT).
Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.